Experience

Oligo Medic

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • Sep 2021 - Present

  I oversee the design and preclinical development of highly targeted drug/mRNA/siRNA delivery systems for modulating cellular processes and combating diseases. This involves employing polymer modifications, nanoparticle synthesis, and incorporating ligands/peptides/antibodies for precise targeting. I lead the comprehensive process development of nanoparticle preparation, ensuring rigorous physicochemical characterization, yield optimization, and purity maintenance. Additionally, I conduct in-depth preclinical assessments to evaluate the safety, exceptional targeting capabilities, and robust therapeutic efficacy of the nanoparticles in both in vitro and in vivo models. As a secondary project, I also employ primary and stem cell technologies to monitor cell expansion, viability, self-renewal, and differentiation towards desired lineages in injectable hydrogels for implantable therapeutic device development. Show less



McGill Genome Centre

• Canada
• Research
• 1 - 100 Employee

• Postdoctoral Researcher

  • Sep 2020 - Oct 2021

  I applied innovative micro and nanotechnologies to investigate and manipulate cells, and proteins, aiming to identify new biomarkers for early disease detection and develop affordable point-of-care diagnostics. Through microfabrication techniques, I successfully isolated and analyzed circulating tumor cells (CTCs) from clinical samples, revealing significant phenotypic CTC biomarkers. By optimizing ELISA and single-cell imaging affinity proteomics with DNA-barcoded antibodies, I ensured the reliability of the assay through validation with commercial ELISA kits and flow cytometry. This approach enabled the targeting of more than 20 proteins in various cancer-related cell types and extracellular vesicles. Show less



McGill University

• Canada
• Higher Education
• 700 & Above Employee

• Doctoral Researcher

  • Sep 2015 - Sep 2020

  I leveraged my expertise to investigate cellular behavior, signaling pathways and their underlying effects on stem cell differentiation and oncogenic transcription activation. I integrated modern cell therapy and advanced cell imaging technologies to visualize and track cellular behavior and unravel the regulatory mechanism of nucleocytoplasmic transport of transcriptional regulators such as YAP1 which plays a key role in cell fate decision, tissue homeostasis, and oncogenesis. I also performed experiments to elucidate the intricate interplay between protein expressions, nuclear permeability, cellular tension, chromatin states, and YAP1 activity, as well as their implications on stem cell differentiation and oncogenic transcription activities. Show less

• Researcher , Collaboration, Laval, Canada

  • Jan 2018 - Sep 2019

  I conducted a thorough evaluation of a clinically approved medical device to assess its effectiveness in stem cell therapy. Specifically, I focused on studying the impact of physical and biochemical signals on the phenotypic response of human bone marrow-derived mesenchymal stem cells (hMSCs) within the 3D model. I investigated parameters such as cell adhesion, migration, survival, self-renewal, and differentiation towards specific lineages, utilizing the medical device. I conducted a thorough evaluation of a clinically approved medical device to assess its effectiveness in stem cell therapy. Specifically, I focused on studying the impact of physical and biochemical signals on the phenotypic response of human bone marrow-derived mesenchymal stem cells (hMSCs) within the 3D model. I investigated parameters such as cell adhesion, migration, survival, self-renewal, and differentiation towards specific lineages, utilizing the medical device.



Pasteur Institute of Iran

• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Research Associate at National Cell Bank of Iran

  • Sep 2012 - Sep 2014

  My research focused on the application of injectable hydrogels in tissue engineering, specifically for stem cell therapy and the treatment of osteoarthritis defects. Through comprehensive preclinical studies, I systematically evaluated the cytotoxicity of the injectable hydrogels, ensuring their safety and biocompatibility for therapeutic use. I successfully encapsulated adipose-derived stem cells within injectable hydrogels, investigating their potential to promote chondrogenic and osteogenic differentiation in the context of osteoarthritis treatment. Show less